Specific antitumor effects of tumor vaccine produced by autologous dendritic cells transfected with allogeneic osteosarcoma total RNA through electroporation in rats

Cancer Biology and Therapy

Volumn 8, Issue 10, 2009, Pages 973-980

  Yu, Zhe ^a   Sun, Honghui ^a   Zhang, Ting ^b   Yang, Tongtao ^a   Long, Hua ^a   Ma, Bao'an ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Unit 68054 of Chinese PLA Lanzhou Military Area Command   (China)

Author keywords

Allogeneic; Autologous; Cytotoxic T lymphocytes; Dendritic cell; Immunotherapy; Osteosarcoma; RNA

Indexed keywords

CD8 ANTIGEN; DENDRITIC CELL VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; MONOCLONAL ANTIBODY; OKT 8; RNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE GRAFT; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ELECTROPORATION; GENETIC TRANSFECTION; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOSARCOMA; RAT; SENSITIVITY AND SPECIFICITY; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR REJECTION; VACCINE PRODUCTION;

ANIMALS; BONE NEOPLASMS; CANCER VACCINES; CELL FUSION; CELL LINE, TUMOR; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ELECTROPORATION; FEASIBILITY STUDIES; IMMUNOTHERAPY; MALE; OSTEOSARCOMA; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049123389     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.10.8281     Document Type: Article

References (42)

1. Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front Biosci 2007; 1:4050-60.
2. Kim CH, Hong MJ, Park SD, Kim CK, Park MY, Sohn HJ, et al. Enhancement of antitumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006; 55:1309-19.
3. Yokomine K, Nakatsura T, Minohara M, Kira J, Kubo T, Sasaki Y, et al. Immunization with heat shock protein 105-pulsed dendritic cells leads to tumor rejection in mice. Biochem Biophys Res Commun 2006; 343:269-78.
4. Yu Z, Ma B, Zhou Y, Zhang M, Qiu X, Fan Q. Activation of antitumor cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous osteosarcoma. Exp Oncol 2005; 27:273-8.
5. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000; 165:1705-11.
6. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 2003; 7:498-505.
7. Ribas A. Clinical trials with tumor antigen genetically modified dendritic cells. Semin Oncol 2005; 32:556-62.
8. Müller MR, Grünebach F, Nencioni A, Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol 2003; 170:5892-6.
9. Jarnjak-Jankovic S, Saebøe-Larssen S, Kvalheim G, Gaudernack G. mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA. Cytotherapy 2007; 9:587-92.
10. Hu Y, He Y, Srivenugopal KS, Fan S, Jiang Y. In vitro antitumor cytotoxic T lymphocyte response induced by dendritic cells transduced with DeltaNp73alpha recombinant adenovirus. Oncol Rep 2007; 18:1085-91.
11. Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther 2005; 12:699-707.
12. Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther 2005; 12:579-91.
13. Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483-94.
14. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13:905-18.
15. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6.
16. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11:4160-7.
17. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30:749-61.
18. Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, et al. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm 2004; 19:581-8.
19. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55:1432-42.
20. Amano T, Kajiwara K, Yoshikawa K, Morioka J, Nomura S, Fujisawa H, et al. Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model. J Neurosurg 2007; 106:638-45.
21. Landi A, Babiuk LA, van Drunen Littel-van den Hurk S. High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol 2007; 82:849-60.
22. Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J. Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 2006; 8:580-8.
23. Fan QY, Ma BA, Zhou Y, Zhang MH, Hao XB. Bone tumors of the extremities or pelvis treated by microwave-induced hyperthermia. Clin Orthop 2003; 406:165-75.
24. Varan A, Yazici N, Aksoy C, Gedikoglu G, Yalçin B, Akyüz C, et al. Treatment results of pediatric osteosarcoma: twenty-year experience. J Pediatr Orthop 2007; 27:241-6.
25. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007; 19:341-6.
26. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 2008; 10:315-27.
27. Mori K, Rédini F, Gouin F, Cherrier B, Heymann D. Osteosarcoma: current status of immunotherapy and future trends. Oncol Rep 2006; 15:693-700.
28. Bramwell VH. Osteosarcomas and other cancers of bone. Curr Opin Oncol 2000; 12:330-6.
29. Yu Z, Ma B, Zhou Y, Zhang M, Long H, Wang Y, et al. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity. Cancer Invest 2007; 25:535-41.
30. Zhang Y, Ma B, Zhou Y, Zhang M, Qiu X, Sui Y, et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007; 105:277-86.
31. Sousa-Canavez JM, Canavez FC, Leite KR, Camara-Lopes LH. Therapeutic dendritic cell vaccine preparation using tumor RNA transfection: a promising approach for the treatment of prostate cancer. Genet Vaccines Ther 2008; 6:2.
32. Michiels A, Tuyaerts S, Bonehill A, Heirman C, Corthals J, Thielemans K. Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. Methods Mol Biol 2008; 423:155-63.
33. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55:1432-42.
34. Javorovic M, Pohla H, Frankenberger B, Wölfel T, Schendel DJ. RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol Ther 2005; 12:734-43.
35. Benencia F, Courrèges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008; 6:21.
36. Rols MP. Electropermeabilization, a physical method for the delivery of therapeutic molecules into cells. Biochim Biophys Acta 2006; 1758:423-8.
37. Dass CR, Khachigian LM, Choong PF. c-Jun Is critical for the progression of osteosarcoma: proof in an orthotopic spontaneously metastasizing model. Mol Cancer Res 2008; 6:1289-92.
38. Dass CR, Ek ET, Choong PF. Human xenograft osteosarcoma models with spontaneous metastasis in mice: clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol 2007; 133:193-8.
39. Klenke FM, Merkle T, Fellenberg J, Abdollahi A, Huber PE, Gebhard MM, et al. A novel model for the investigation of orthotopically growing primary and secondary bone tumours using intravital microscopy. Lab Anim 2005; 39:377-83.
40. Crnalic S, Häkansson I, Boquist L, Löfvenberg R, Brostrom LA. A novel spontaneous metastasis model of human osteosarcoma developed using orthotopic transplantation of intact tumor tissue into tibia of nude mice. Clin Exp Metastasis 1997; 15:164-72.
41. Grünebach F, Müller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther 2003; 10:367-74.
42. Müller MR, Grünebach F, Nencioni A, Brossart P. Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J immunol 2003; 170:5892-6.